Rubella

Rubella, also known as German measles or three-day measles, is a highly contagious viral infection caused by the rubella virus, a single-stranded RNA virus in the genus Rubivirus. The disease is vaccine-preventable and primarily affects the respiratory system before disseminating throughout the body. Human-to-human transmission occurs through airborne respiratory droplets from coughing or sneezing, with only humans serving as the natural reservoir.

In children and adults, rubella typically presents as a mild illness characterized by a maculopapular rash that begins on the face and spreads to the trunk and limbs, lasting approximately three days. Low-grade fever below 39°C, swollen lymph nodes particularly behind the ears and in the neck, mild conjunctivitis, and occasionally nausea accompany the rash. Adults, especially women, may develop arthritis and painful joint symptoms lasting three to ten days. Complications, though uncommon, can include bleeding disorders, testicular swelling, encephalitis, and nerve inflammation. The incubation period ranges from two to three weeks after exposure, with the virus spreading systemically within five to seven days of infection.

In 2022, an estimated 17,865 rubella cases were reported across 78 countries despite the availability of a safe and cost-effective vaccine. Global rubella vaccine coverage reached approximately 69% by January 2024, with 175 of 194 countries having introduced the vaccine into national immunization programs. The WHO Region of the Americas was declared free of endemic rubella transmission in 2015, representing the first region to achieve this milestone. The Measles & Rubella Partnership has contributed to an estimated 57 million lives saved since 2000 through vaccination efforts. Before widespread vaccination, up to 4 babies per 1,000 live births were born with congenital rubella syndrome in some populations.

Rubella spreads primarily through respiratory droplets when infected individuals cough or sneezes. Persons are infectious during approximately one week before rash onset and for about one week after the rash appears. Infants with congenital rubella syndrome may shed the virus for more than a year, extending potential transmission windows. The virus replicates in the nasopharynx and lymph nodes before disseminating throughout the body.

Pregnant women without immunity face the highest risk of adverse outcomes, with a 90% chance of fetal transmission when infected during early pregnancy. Women of childbearing age in regions with low vaccination coverage are particularly vulnerable to congenital rubella syndrome outcomes, including miscarriage, fetal death, stillbirth, and infants with multiple birth defects. Infants born with congenital rubella syndrome may experience lifelong disabilities including hearing impairment, cataracts, cardiac defects, autism, diabetes, and thyroid dysfunction requiring ongoing medical intervention. Adults, especially women, are at increased risk for arthritis complications compared to children.

Vaccination with a live attenuated rubella vaccine is the primary and most effective prevention strategy, providing more than 95% long-lasting immunity comparable to natural infection. The vaccine is available in monovalent form or commonly in combination formulations such as MMR (measles, mumps, rubella) or MMRV (measles, mumps, rubella, varicella). The WHO recommends the first dose at 12 to 18 months of age with a second dose at 36 months. Adverse reactions are generally mild and may include injection site pain, low-grade fever, rash, and muscle aches. Mass immunization campaigns have proven effective in reducing disease incidence and congenital rubella syndrome burden.

Rubella surveillance should be integrated with existing measles surveillance systems given their overlapping clinical presentations and epidemiological profiles. Monitoring should include tracking of rash illnesses, particularly in women of childbearing age, and systematic reporting of congenital rubella syndrome cases. The 97% decline in reported rubella cases from 670,894 in 102 countries reflects both vaccination impact and surveillance improvements, though case detection remains variable across regions. Surveillance data inform vaccination program performance assessment and elimination verification efforts.

1. 1 WHO Fact Sheet. Rubella.
2. 2 WHO Q&A. News.
3. 3 Wikidata. rubella.
4. 4 Wikipedia. Rubella - Wikipedia.

ICD-10

B06

ICD-11

KA63

Total cases

268K

Total deaths

7

Peak month

2011-05

Coverage

4 reporting countries · 2000-01-01 → 2026-05-09